Treatment on-demand

VONVENDI® was tested in a clinical trial for on-demand treatment.1

Real VWD patient Leslie standing on a rock with her outdoor outfit shares her on-demand treatment with VONVENDI®.

Trial design

VONVENDI, given with and without additional recombinant FVIII (rFVIII), was studied in 22 adult patients with different types of severe von Willebrand disease (VWD) to test how it would work to control a total of 192 bleeds. The first dose of VONVENDI was given with rFVIII; if further doses were necessary, rFVIII was given only when needed. Investigators rated bleed resolution according to a scale of "Excellent=1," "Good=2," "Moderate=3," or "None=4." Treatment success was defined as a mean efficacy rating score of less than 2.5 for all bleeding episodes.1,2

Circle with 100% progress completion.

100% of people (18/18) had their bleeds successfully treated1b

Circle with 96.9% progress completion.

96.9% of 192 bleeds were rated as "Excellent," with the remaining 3.1% rated as "Good"1

Circle with 81.8% progress completion.

81.8% of 192 bleeds were cleared up after just one infusion (ranges 1-4)1a

aYour doctor will decide if you may use VONVENDI by itself, or if you also require rFVIII along with VONVENDI, based on your clinical situation.1

bThis analysis excluded 4 of a total of 22 patients who were treated with VONVENDI in the trial.1

In the clinical study, an average of one infusion of VONVENDI (with or without rFVIII) (ranges 1-4) treated mild-to-moderate bleeding episodes. People who experienced a major bleed required an average of two doses (range 1-3 doses). In two cases, as many as three doses were needed to control bleeding.1

Treat and control bleeding
episodes on-demand

VONVENDI can be used on-demand by adults with VWD to control major
and minor bleeds in all locations, such as1:

Tooth icon.

Mouth bleeds

Nose icon.

Nose bleeds

Uterus icon.

Heavy menstrual
bleeds

Colon icon.

GI bleeds

Joints icon.

Joint bleeds

Ready to talk to your healthcare provider?

Our easy-to-use Discussion Guide, used alongside our bleed tracker, can help you speak to your healthcare provider about finding a treatment that's right for you.

Download the guide
Von Willebrand disease discussion guide.
Headshot of Leslie, Real VWD patient smiling.

Leslie's story

Diagnosed with VWD in 2003

"Once I was trained on how to do my own infusion, I infused on the eve of the surgery and again right before. I also infused after surgery—this was my normal for any surgery. I was amazed at how well this treatment worked for me."

"I try not to let my blood disorder get me down. As I tell my son, life is what you make of it. My adventure is not done; my story is not finished."

See her story
Headshot of Erica, Real VWD patient smiling.

Erica's story

Diagnosed with VWD in 1981

"I feel fortunate that there's been an increase in awareness when it comes to VWD, from diagnosis and available information to patient care."

"The doctor came back with a diagnosis: VWD type 2B. It was something I had never heard of before… but something that would change my life forever."

See her story
Headshot of Nicole, Real VWD patient smiling.

Nicole's story

Diagnosed with VWD in 2009

"Although I've faced many battles since I was diagnosed, the amount of support I had from all the other patients fighting the same battle gave me strength."

"I was experiencing nosebleeds that lasted 15 minutes or more almost every day. My new doctor told me I needed to manage my bleeds, and discussed beginning a treatment called VONVENDI."

See her story
Doctor talking about VONVENDI® for surgical use.
Surgical use efficacy

A clinical trial tested VONVENDI in adults
with VWD undergoing surgery.1

Learn more
Doctor going over documents with her patient.
VONVENDI safety

See the most common side effects.

Learn more

References

  1. VONVENDI Prescribing Information
  2. Gill JC, Giancarlo C, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2045.
divider line between content and footer